Previous Engagers

Engage offers bespoke meet ups tailored so audience curation can meet your specific business objectives. These informal and exclusive networking events provide opportunities for you to engage attendees by demonstrating your business capabilities, then strengthen and form new connections with the most influential in the industry.

We have ventured far and wide to deliver bespoke events for our partners, here’s a list of the past Engagers and News & Brews.

April 2022

Roche PHCS News & Brews is an exclusive event series, providing leaders in pharma and biotech the opportunity to connect with industry thought leaders and explore the latest innovations in technologies that facilitate the advancement of precision medicine.

The Stilla Technologies Engager has been created as an exclusive invitation-only event to provide biopharma Directors, Heads and VPs working in Translational Research and Oncology departments with the opportunity to participate in the conversation around the benefits of multiplexing in dPCR.

Join this Engager to learn how multiplexed dPCR can help you take the next step from NGS to routine testing, as well as evaluating current evidence on innovative technologies to improve detection, prognosis, disease monitoring, and drug development.

Far from being a conference or seminar, the idea is to have a structured discussion about the biggest challenges in the liquid biopsy field, before connecting over a few appetizers and drinks!

Welcome to the PathAI Engager, an exclusive event providing pharmaceutical leaders with the chance to explore opportunities of AI-powered pathology for research and clinical development.

Spend an evening with leading experts in the field discussing best practices and examples of AI applications over a few appetizers and drinks!

This is your chance to be at the heart of the discussion by joining your peers within the translational medicine and clinical development arena to highlight how AI-powered pathology can enhance clinical opportunity and improve the delivery of precision medicine.

Welcome to the Abcam Engager, an invitation-only networking event providing Directors, Heads and C Level Executives in translational research and clinical development departments in biotechs with the opportunity to explore how to improve the delivery of the next big drug to market.

Join this exclusive Engager to find out how to remove unnecessary hurdles to move up in the drug development pathway while highlighting the importance of a strong partner ecosystem.

Abcam will facilitate the KOL panel’s forward-looking discussion tackling the challenges around the drug discovery and development journey before opening it up to questions and answers from the audience while connecting and networking over a few appetizers and drinks.

February 2022

The Stilla Technologies Engager has been created as an exclusive invitation-only event to provide academics and biopharma Heads, Directors, and VPs working in Translational Research and Oncology departments with the opportunity to participate in the conversation around the benefits of multiplexing in dPCR and address unmet needs in multiplex testing to improve clinical outcomes.

The Pharma Executive Networking Event is an exclusive event created to provide Directors, VPs, and Functional Executives within pharma with the opportunity to discuss and evaluate the clinical trial use cases for ctDNA MRD and learn how they can unlock a new clinical trial paradigm.

January 2022

Guardant Health Engager is an exclusive limited-attendance event that focuses on the impact of disruptive, data driven biomarker-based strategies to accelerate drug development and improve cancer patient care. We are inviting to this event high-level executives from BioPharma focused on breast cancer and based in the US and Europe.

December 2021

The Stilla Technologies Engager has been created as an exclusive invitation-only event to provide biopharma Senior Scientists, Directors, and VPs working in Translational Research and Oncology departments with the opportunity to participate in the conversation around the benefits of multiplexing in dPCR.

Learn more here.

This Labcorp Oncology Engager has been created as an exclusive online event to provide C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leaderships of German and Austrian Immuno-Oncology biotechs with key learnings and takeaways on trial design concepts and biomarker considerations for optimising development strategy and Go / No-Go decisions for agents in the preclinical space, regulatory framework considerations and accelerating the development of new IO therapies.

Learn more here.

November 2021

This Labcorp Engager has been created as an exclusive online event to provide you with the latest insights and innovations on how to take an enterprise approach to seamlessly design and implement decentralized clinical trials. Learn new ways to broaden your global patient reach and diversity, streamline data collation and analysis, as well as accelerate time to market for new drugs and therapies.

Learn more here.

This Engager has been created as an exclusive event to provide C-level Executives, Directors, and Heads of Biomarkers, Neurological disorders, and cell and gene therapy in biopharma with the opportunity to delve deep into the challenges and solutions in bringing effective diagnostic and therapeutic to market for complex neurodegenerative diseases.

Learn more here.

Join this exclusive Engager to find out how these HTS multiplexed immunoassays can cost effectively help improve data quality. Real-world examples of the advantages of using highly multiplexed no-wash immunoassays will be discussed and how their use can lead to reproduceable and reliable data.

Learn more here.

September 2021

With the European Union’s In Vitro Diagnostics Regulation (IVDR) set to go into full effect in May 2022, Roche Diagnostics has led the industry in its proactive approach to understanding the requirements involved in certification and deep investment in transitioning its portfolio of CE-marked IVD products.  In the process, it has gained critical expertise in the unique and complex challenges presented in ensuring compliance for companion diagnostics (CDx) assays.  This Roche CDx News & Brews will shed light on fundamental considerations for biopharma companies and how key lessons learned from Roche’s journey can be applied to navigate CDx development and registration in the IVDR era.

Learn more here.

July 2021

Accelerating Immuno-Oncology drug development leveraging preclinical strategy to de-risk the clinical programme has been driven through evolution in regulatory framework, deeper understanding of cancer and re-defining key endpoints for success in Immuno-Oncology.

Learn more here.

June 2021

With the lack of approved CDx for liquid biopsy and a complex regulatory process in China, it has proven challenging for global biopharma companies to make strategic clinical trial plans as well as to truly vet and select capable partners that can help navigate the end-to-end process of running global clinical trials involving China. Join this Engager to hear some specific examples of challenges, learn how to overcome them and stay ahead of the curve with future landscape changes to maximize your chance of success as you embark on your journey of running global trials involving China and US.

Learn more here.

May 2021

Join Agilent Technologies for a deep dive with pharma to discuss the key considerations for successful drug and companion diagnostic co-development and commercialization programs using a broad set of analytical tools.

In this exclusive online event, expert speakers will address key opportunities to integrate different technologies from discovery through clinical trials to global manufacturing and commercialization.

Learn more here.

This event will delve into the short and long-term strategic decisions that drive your diagnostic investments in the next 3-5 years. For instance, our KOL panel will discuss biomarker-informed patient treatments across the continuum of patient care, and in support of such disruptive treatments, the underlying technological advances and innovative partnership models across drug and diagnostic developers, medical centers and payors.

Learn more here.

From regulatory pathways, biomarker strategies to trial designs & the integration of decentralized solutions, join the Covance by Labcorp Engager to explore strategies that have been successful in responding to cancer patient needs by compressing timelines for study delivery and achieving accelerated oncology drug development.

Learn more here.

Drugs targeting the PD-1/PD-L1 pathway have revolutionized the treatment of multiple cancer types including non-small cell lung cancer, renal cancer and melanoma. Dr. van den Bosch’s presentation will explore how more information may be revealed by setting up the PD-1/PD-L1 Proximity assay in combination with chromogenic IHC multiplexing as detailed in a recent publication that investigated tumor draining lymph nodes of melanomas and the primary tumors with proximity and chromogenic IHC multiplexing.

Learn more here.

April 2021

Providing perspectives from leading experts in the field, join this Engager to learn about how biomarker determination for patient recruitment and stratification can be improved, have a discussion on how PathAI Algorithms can be used for quality monitoring in clinical trials and delve into the advantages of using PathAI’s AI-Powered Platform to overcome the variability and subjectivity of manual pathology reads.

Learn more here.

March 2021

With 90% of IND applications currently failing approval processes and leading to repeated R&D failures in the lab, diminished likelihood of success in clinical trials, and/or inappropriate diagnosis and treatment of patients in the clinic, join this Engager to benchmark against the current state of genomic research and drug development. Don't miss out on your chance to discover how you can improve your genomic strategy to establish more efficacious clinical trials and increase the chance of FDA approval with genetic evidence support.

Learn more here.

February 2021

Providing perspectives from leading experts in the field, join this Engager to learn about the benefits of using MRD assays in clinical trials and discuss how they can be used to enrich group testing of new therapies. Delve into the advantages of using ctDNA approaches for both clinical trial selection and monitoring, and how they can provide complimentary information in differential clinical trial applications.

Learn more here.

January 2021

How does multiplexing fit into the modern pathology laboratory workflow? How can multiplexing increase predictive power of slide-based tissue biomarkers? Address these questions and more alongside your biopharma peers throughout this interactive digital event. Join to be equipped with the latest actionable insight you can take away to your teams about the current state of multiplexing and have a discussion on what is currently being done, longer-term aspirations and where the future could take us.

View more here.

November 2020

Join the latest in the series of Roche News & Brews Events, hosted by Roche Diagnostics, for a conversation with Eric Glassy, MD, FCAP, Medical Director, Affiliated Pathologists Medical Group, Jason Adams, VP/Head of CDx Partnering, Roche Molecular Systems, and Michael Rivers, VP/Lifecycle Leader, Digital Pathology, Roche Tissue Diagnostics.

Explore the latest insights and innovations facilitating the advancement of digital pathology and its application in therapeutic development and clinical treatments to see how you can go beyond a one-size-fits-all approach.

Ensure your research teams are utilizing the full potential of the latest in digital pathology techniques and join this interactive online event to bring the latest actionable insight back to your teams and accelerate the clinical adoption of digital pathology technology as a crucial diagnostic tool for oncology therapeutics.

View more here...

October 2020

CDx Engage - Covance Illumina Engager 6 Oct Upcoming v2

Join this Covance and Illumina Engager, for a conversation with Mark Roberts, Senior Director, Diagnostics Development, Covance and Volker Liebenberg, Director, Medical Affairs EMEA, Illumina, addressing the attractive promise of precision oncology, the fast paced and ever-changing clinical development environment presents significant challenges for targeted treatment development. Where is clarity needed to allow pharma to pursue biomarker strategies to see clinical and commercial success?

Address this question and more alongside your drug development peers throughout this interactive online event. Join to be equipped with the latest actionable insight you can take away to your teams to accelerate innovative new biomarkers into clinical adoption, improve testing validation and fine-tune your clinical trial design to see improved experience and engagement.

View more here...

September 2020

Join this Guardant Health Engager, and guest speaker, Clara Montagut from Hospital Del Mar, Spain, as they take you on a deep dive into the new, emerging and transformative opportunities liquid biopsy applications hold for the future of cancer care.

With recent FDA approvals highlighting the patient stratification and predictive power of these technologies, expect to be equipped with latest expert insight on applying such techniques to see more robust clinical outcomes.

View more here...

Covance hosted their Engager, with a conversation with Suso Platero, Global Leader, Precision Medicine and Head, Biomarker Solution Center and Companion Diagnostics, Covance and Jeff Conroy, Chief Scientific Officer, OmniSeq Inc.®, Director, Genomics Technologies, Roswell Park Comprehensive Cancer Center, addressing key opportunities to refine study and assay design enabling you to carry your biomarker through all the way to commercialization.

As technological improvements reveal more about the genomic drivers underpinning disease, biomarkers are playing an increasingly important role in cancer care decision making. Despite the predictive and prognostic value of these markers well realised, challenges still exist with their clinical implementation, stalling the development of therapies targeting aberrant disease pathways.

View more here...

Covance hosted their Engager, with a conversation with Mark Roberts, Senior Director, Diagnostics Development, Covance and Taylor Jensen, Director, Research and Development, Integrated Oncology, addressing key opportunities to refine study and assay design enabling you to carry your biomarker through all the way to commercialization.

As technological improvements reveal more about the genomic drivers underpinning disease, biomarkers are playing an increasingly important role in cancer care decision making. Despite the predictive and prognostic value of these markers well realised, challenges still exist with their clinical implementation, stalling the development of therapies targeting aberrant disease pathways.

View more here...

Roche CDx hosted their September’s News & Brews with Dr. Max Diehn, Stanford University School of Medicine.

While recent years have seen advances in diagnosis and treatment lead to improved survival rates for many early stage cancer types, there is an important need for earlier detection so that patients most at risk of relapse can avoid unnecessary disease recurrence and progression.

Insights came from Dr. Diehn on the transformative potential of ctDNA as a biomarker enabling the detection, diagnosis and monitoring of disease for timely and targeted treatment interventions.

View more here...

More exciting updates coming soon!